An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Trastuzumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 01 Aug 2016 Status changed from completed to discontinued.
- 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.